comprehensive -WSS

comprehensive

author：hotspot 2025-09-29 20:52:43 - browse：151

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： FDA needs staff influx to meet gene therapy needs, Marks says

WSS

NIH chief: government has fallen behind pharma on clinical trials

FDA reorg will put new emphasis on investigations, sources say

Study suggests Covid rebound is far more common with Paxlovid than without

After decades in use, heart stents finally beat placebo

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

The woman behind the Dana Farber

hotspot

comprehensive

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medicare’s new pay boost for primary care is angering specialists

Alkermes shareholders re

In diabetes hearing, Sanders takes on a new foe: food makers

The cancer drug shortage isn’t new — and neither are the solutions

Pfizer plans to depart BIO

In Memoriam: Notable people who died in 2023

Healthy food access boosts outcomes in two studies

hotspot

How state and local governments are sidelining science

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Experimental asthma app from Apple and Anthem shows promise

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Radiology is caught between AI's potential and concern for patients

After decades in use, heart stents finally beat placebo

focus

focus

focus

explore